La vendita allo scoperto per NuGen Medical Devices dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di NuGen Medical Devices. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

NuGen Medical Devices (OTC:NGMDF) Azioni, Report sulle vendite allo scoperto

NuGen Medical Devices Inc is a medical device manufacturing company specializing in the field of needleless injections and related technologies. The reportable segment of the company is the manufacturing of needless injector devices. Geographically the company generates revenue from Europe followed by Asia, North America and others.

NUGEN MED DEVICES INC by NUGEN MED DEVICES INC.

NuGen Medical Devices Inc

Universal Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UEIC#NASDAQ">UEIC</a>) is looking for Q4 GAAP EPS of $(0.27)-(0.17) vs $(0.07) analyst estimate. seessales of $99.000 million-109.000 million.

News

Guidance

UEIC

Universal Electronics Sees Q4 GAAP EPS $(0.27)-(0.17) vs $(0.07) Est; Sees Sales $99.000M-109.000M

Contracts

WFRD

Weatherford Announces Three-Year Contract with ADNOC, Financial Terms Not Disclosed

CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) is looking for FY2024 Adj EPS of $1.67-1.73 vs $1.64 analyst estimate. sees sales of $885.000 million-905.000 million vs $883.61 million estimate.

CARG

CarGurus Sees FY2024 Adj EPS $1.67-1.73 vs $1.64 Est; Sees Sales $885.000M-905.000M vs $883.61M Est

Highlighting Tumor-Targeted T Cell Activation and CD40 Modulation in Solid Tumors at SITC 2024

Biotech

General

MOLN

Molecular Partners Unveils Preclinical Proof-Of-Concept For CD3 Switch-DARPin T Cell Engager And Clinical Biomarker Insights For MP0317

Sprout Social Sees Q4 Revenue $106.3M-$107.1M; Q4 Adj. EPS $0.15-$0.16.

Ameresco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>) affirms FY2024 Adj EPS guidance from $1.15-1.35 to $1.15-1.35 vs $1.14 analyst estimate. Affirms FY2024 sales outlook from $1.70 billion-1.80 billion to $1.70 billion-1.80 billion vs $1.74 billion estimate.

AMRC

Ameresco Affirms FY2024 Adj EPS Guidance from $1.15-1.35 to $1.15-1.35 vs $1.14 Est; Affirms FY2024 Sales Guidance from $1.70B-1.80B to $1.70B-1.80B vs $1.74B Est

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.49) by 77.55 percent. This is a 69.44 percent increase over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $88.83 million which beat the analyst consensus estimate of $84.14 million by 5.58 percent. This is a 5.80 percent increase over sales of $83.97 million the same period last year.

Earnings

Earnings Beats

INGN

Inogen Q3 Adj $(0.11) Beats $(0.49) Estimate, Sales $88.83M Beat $84.14M Estimate

CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) is looking for Q4 Adj EPS of $0.50-0.55 vs $0.46 analyst estimate. sees sales of $219.000 million-239.000 million vs $225.58 million estimate.

CarGurus Sees Q4 Adj EPS $0.50-0.55 vs $0.46 Est; Sees Sales $219.000M-239.000M vs $225.58M Est

W&T Offshore Sees FY24 Total Equivalents (MBoe) 11,900 – 13,267

W&T Offshore Sees Q4 Total Equivalents (MBoe) 2,927-3,253

IONQ

IonQ Partners With imec To Enhance Quantum Computing Scale And Performance Using Photonic Integrated Circuits, Aiming To Increase Qubit Count, Improve System Efficiency, And Reduce Costs For Next-Gen Quantum Computers

Sprout Social Sees FY24 Revenue $405.1M-$405.9M Vs $405.535M Est; FY24 Adj. EPS $0.46-$0.47 Vs $0.46 Est.

FY2025 Guidance
&nbsp;
<ul>
<li>The Company is providing preliminary FY2025 guidance of $12.00 Adjusted Net Income per Diluted Share with the expectation of being a full corporate taxpayer throughout the year (20%-25% effective tax rate).</li>
</ul>

SEZL

Sezzle Is Providing Preliminary FY25 Guidance Of $12.00 Adjusted Net Income Per Diluted Share With The Expectation Of Being A Full Corporate Taxpayer Throughout The Year (20%-25% Effective Tax Rate) Vs $10.09 Est.

SEMR

SEMrush Sees Q4 Total Revenue $100.8M-$101.8M vs $101.03M Est., Sees FY24 Total Revenue $375M-$376M vs $374.45M Est.

Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) reported its third-quarter results after Thursday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/11/b41823717/block-announces-third-quarter-2024-results">details from the report.&nbsp;</a>
The Details:&nbsp;Block reported quarterly earnings of 88 cents per share, which beat the analyst consensus estimate of 87 cents. Quarterly revenue came in at $5.97 billion which missed the analyst consensus estimate of $6.24 billion and is an increase over sales of $5.617 billion from the same period last year.
<ul>
<li>Square generated a gross profit of $932 million, up 16% year-over-year.</li>
<li>Cash App generated a gross profit of $1.31 billion, up 21% year-over-year.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
&#8220;We outperformed our gross profit and profitability guidance in the third quarter of 2024. Gross profit grew 19% year over year to $2.25 billion. Cash App continued its strong performance with gross profit growth of 21% year over year, driven primarily by growth in inflows per active and an increase in monetization rate,&#8221; Block wrote in a letter to shareholders.
&#8220;There was strong performance across Cash App Card, Cash App Borrow and our BNPL platform. Square gross profit grew 16% year over year in the third quarter, in line with our expectations, behind strength in our software and integrated payments and banking products,&#8221; the company added.
SQ Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Block shares are down 7.69% after-hours at $69.25 at the time of publication Thursday.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Photo: Shutterstock

Fintech news covering the emerging Financial Technology services sector

Fintech

After-Hours Center

Movers

Block Shares Sink After Mixed Q3 Results: EPS Beat, Revenues Miss

nLight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASR#NASDAQ">LASR</a>) sees Q4 sales of $49.000 million-54.000 million vs $59.88 million estimate.

LASR

nLight Sees Q4 Sales $49.000M-54.000M vs $59.88M Est

Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $(0.01) by 100 percent. The company reported quarterly sales of $65.200 million which missed the analyst consensus estimate of $67.555 million by 3.49 percent. This is a 2.49 percent decrease over sales of $66.865 million the same period last year.

Earnings Misses

MRVI

Maravai LifeSciences Q3 2024 Adj. EPS $(0.02) Misses $(0.01) Estimate, Sales $65.200M Miss $67.555M Estimate

Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) System-wide sales are expected to be between $525 million and $535 million.

JYNT

Joint Corp. FY 2024 System-wide sales are expected to be between $525 million and $535 million.

Updated FY2024 Guidance
&nbsp;
<ul>
<li>The Company is raising several components of its FY2024 guidance due to: 1) continued sustained growth, and 2) the inclusion of the newly launched banking program with WebBank, which was not accounted for in previous guidance.</li>
<li>&nbsp;
<ul>
<li>Net Income: $71.5 million versus $55.0 million provided with 2Q24 earnings.</li>
</ul>
</li>
<li>&nbsp;
<ul>
<li>Net Income per Diluted Share: $12.05 versus $9.25 provided with 2Q24 earnings.</li>
</ul>
</li>
<li>&nbsp;
<ul>
<li>Total Revenue Growth: 55% versus 35%-40% provided with 2Q24 earnings.</li>
</ul>
</li>
<li>&nbsp;
<ul>
<li>Total Revenue Less Transaction Related Costs as a percentage of Total Revenue: No change to the 55% provided with 2Q24 earnings.</li>
</ul>
</li>
<li>Additionally, updating the FY2024 guidance for the following metrics that adjust for certain significant gains, losses, and charges that may not directly correlate to the underlying performance of the Company's business:</li>
<li>&nbsp;
<ul>
<li>Adjusted Net Income<a href="http:/#_ftn2">[2]</a>: $58.0 million versus $40.0 million provided with 2Q24 earnings.</li>
</ul>
</li>
<li>&nbsp;
<ul>
<li>Adjusted Net Income per Diluted Share2: $9.80 versus $6.75 provided with 2Q24 earnings.</li>
</ul>
</li>
<li>The Company expects a mid-single digit annualized effective tax before consideration of discrete tax items for 4Q24.</li>
</ul>

Sezzle Increases FY24 Revenue Growth Guidance From 35%-40% To 55%; Adj. Net Income Per Diluted Share From $6.75 To $9.80 Vs $6.73 Est.; Adj. Net Income From $40M To $58M

FIGS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIGS#NYSE">FIGS</a>) lowers FY2024 sales outlook from $545.65 million-556.56 million to $540.19 million-545.65 million.

FIGS

FIGS Lowers FY2024 Sales Guidance from $545.65M-556.56M to $540.19M-545.65M

NuGen Medical has a needle-free injecting device approved in 40+ countries. Sales are ramping up slowly, but weight loss drug could be a game-changer.

Comments

NuGen Medical Devices

Vendite allo scoperto

NuGen Medical Devices (OTC:NGMDF) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO